



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

TATDN3 siRNA (m): sc-154086

BACKGROUND

TATDN3 (tatD DNase domain containing 3) is a 274 amino acid nuclear protein that belongs to the tatD DNase family and exists as two alternatively spliced isoforms. TATDN3 is a deoxyribonuclease that binds two divalent metal cations per subunit. The gene that encodes TATDN3 contains 24,998 bases and maps to human chromosome 1q32.3. Spanning 260 million base pairs and encoding over 3,000 genes, chromosome 1 comprises nearly 8% of the human genome. Chromosome 1 houses a large number of disease-associated genes, including those that are involved in familial adenomatous polyposis, Stickler syndrome, Parkinson's disease, Gaucher disease, schizophrenia and Usher syndrome. Aberrations in chromosome 1 are found in a variety of cancers, including head and neck cancer, malignant melanoma and multiple myeloma.

REFERENCES

1. Eudy, J.D., Yao, S., Weston, M.D., Ma-Edmonds, M., Talmadge, C.B., Cheng, J.J., Kimberling, W.J. and Sumegi, J. 1998. Isolation of a gene encoding a novel member of the nuclear receptor superfamily from the critical region of Usher syndrome type IIa at 1q41. *Genomics* 50: 382-384.
2. Tayebi, N., Callahan, M., Madike, V., Stubblefield, B.K., Orvisky, E., Krasnewich, D., Fillano, J.J. and Sidransky, E. 2001. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. *Mol. Genet. Metab.* 73: 313-321.
3. Plasilova, M., Russell, A.M., Wanner, A., Wolf, A., Dobbie, Z., Müller, H.J. and Heinemann, K. 2004. Exclusion of an extracolonic disease modifier locus on chromosome 1p33-36 in a large Swiss familial adenomatous polyposis kindred. *Eur. J. Hum. Genet.* 12: 365-371.
4. Betarbet, R., Anderson, L.R., Gearing, M., Hodges, T.R., Fritz, J.J., Lah, J.J. and Levey, A.I. 2008. Fas-associated factor 1 and Parkinson's disease. *Neurobiol. Dis.* 31: 309-315.
5. Yurov, Y.B., Iourov, I.Y., Vorsanova, S.G., Demidova, I.A., Kravetz, V.S., Beresheva, A.K., Kolotii, A.D., Monachov, V.V., Uranova, N.A., Vostrikov, V.M., Soloviev, I.V. and Liehr, T. 2008. The schizophrenia brain exhibits low-level aneuploidy involving chromosome 1. *Schizophr. Res.* 98: 139-147.
6. Holliday, E.G., Nyholt, D.R., Tirupati, S., John, S., Ramachandran, P., Ramamurti, M., Ramadoss, A.J., Jeyagurunathan, A., Kottiswaran, S., Smith, H.J., Filippich, C., Nertney, D.A., Nancarrow, D.J., et al. 2009. Strong evidence for a novel schizophrenia risk locus on chromosome 1p31.1 in homogeneous pedigrees from Tamil Nadu, India. *Am. J. Psychiatry* 166: 206-215.
7. Balcárková, J., Urbánková, H., Scudla, V., Holzerová, M., Bacovský, J., Indrák, K. and Jarosová, M. 2009. Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma. *Cancer Genet. Cytogenet.* 192: 68-72.
8. Yokoi, T., Koide, R., Matsuoka, K., Nakagawa, A. and Azuma, N. 2009. Analysis of the vitreous membrane in a case of type 1 Stickler syndrome. *Graefes Arch. Clin. Exp. Ophthalmol.* 247: 715-718.

CHROMOSOMAL LOCATION

Genetic locus: *Tatdn3* (mouse) mapping to 1 H6.

PRODUCT

TATDN3 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see TATDN3 shRNA Plasmid (m): sc-154086-SH and TATDN3 shRNA (m) Lentiviral Particles: sc-154086-V as alternate gene silencing products.

For independent verification of TATDN3 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-154086A, sc-154086B and sc-154086C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

TATDN3 siRNA (m) is recommended for the inhibition of TATDN3 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor TATDN3 gene expression knockdown using RT-PCR Primer: TATDN3 (m)-PR: sc-154086-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.